E430018J23Rik Inhibitors
Zfp764l1, predicted to exhibit DNA-binding transcription factor activity and regulate transcription by RNA polymerase II, emerges as a critical player in the intricate machinery of gene expression. Its ability to bind specific cis-regulatory regions further underlines its involvement in orchestrating the transcriptional landscape. The predicted nuclear localization suggests a focal point for its activities, likely influencing a myriad of genes involved in RNA polymerase II-mediated transcription. Importantly, Zfp764l1's orthologous relationship with human ZNF764 underscores its evolutionary conservation, implying functional significance across species.
In the context of inhibition, various chemicals have been explored to modulate Zfp764l1's activities. Direct inhibitors like Actinomycin D and α-Amanitin act by directly disrupting RNA polymerase II, impacting Zfp764l1's predicted DNA-binding transcription factor activity and its role in transcriptional regulation. Indirect inhibitors, such as Triptolide and Flavopiridol, target cellular pathways like NF-κB and CDKs, influencing Zfp764l1 through alterations in the broader transcriptional landscape. The intricate mechanisms of inhibition highlight the interconnected pathways through which Zfp764l1 exerts its regulatory influence, offering insights into potential strategies for precise modulation of its functions. Understanding these mechanisms contributes to a deeper comprehension of the gene's role in transcriptional regulation and unveils potential avenues for targeted interventions in gene expression processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Direct inhibitor of RNA polymerase II, impacting Zfp764l1 by preventing the transcription process. Actinomycin D intercalates into DNA, inhibiting RNA synthesis, and subsequently disrupting Zfp764l1's predicted DNA-binding transcription factor activity and its role in regulating transcription by RNA polymerase II. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
Direct inhibitor of RNA polymerase II, interfering with Zfp764l1's ability to bind cis-regulatory regions. α-Amanitin disrupts RNA synthesis by binding to the RNA polymerase II enzyme, leading to inhibition of Zfp764l1's predicted RNA polymerase II cis-regulatory region sequence-specific DNA binding activity and its role in transcriptional regulation. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Inhibits transcription factor NF-κB, indirectly influencing Zfp764l1. Triptolide disrupts the NF-κB pathway, impacting the expression of genes involved in transcriptional regulation by RNA polymerase II, subsequently influencing Zfp764l1's predicted DNA-binding transcription factor activity and its role in transcriptional regulation. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Inhibits cyclin-dependent kinases (CDKs), indirectly impacting Zfp764l1 by modulating cell cycle-related transcription. Flavopiridol disrupts CDK activity, influencing the phosphorylation status of RNA polymerase II and subsequently affecting Zfp764l1's predicted RNA polymerase II-specific DNA binding activity and its role in transcriptional regulation. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
Inhibits p300/CBP histone acetyltransferase, indirectly influencing Zfp764l1. C646 disrupts the acetylation of histones, leading to altered chromatin structure and influencing Zfp764l1's predicted DNA-binding transcription factor activity in the context of RNA polymerase II-mediated transcription. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
Inhibits CDK9, indirectly impacting Zfp764l1 by modulating RNA polymerase II phosphorylation. DRB disrupts the elongation phase of transcription, affecting Zfp764l1's predicted RNA polymerase II-specific DNA binding activity and its role in regulating transcription by RNA polymerase II. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Inhibits DNA topoisomerase I, indirectly impacting Zfp764l1 by inducing DNA damage. Camptothecin disrupts DNA topology, influencing the accessibility of DNA to RNA polymerase II and affecting Zfp764l1's predicted RNA polymerase II-specific DNA binding activity and its role in transcriptional regulation. | ||||||
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $58.00 $204.00 | 15 | |
Inhibits DNA synthesis and repair, indirectly influencing Zfp764l1. Fludarabine disrupts nucleotide metabolism, affecting the availability of substrates for RNA polymerase II-mediated transcription and subsequently modulating Zfp764l1's predicted DNA-binding transcription factor activity and its role in transcriptional regulation. | ||||||
CX-5461 | 1138549-36-6 | sc-507275 | 5 mg | $245.00 | ||
Inhibits RNA polymerase I, indirectly impacting Zfp764l1 through modulation of rRNA synthesis. CX-5461 disrupts nucleolar integrity, influencing the cellular environment for RNA polymerase II-mediated transcription and affecting Zfp764l1's predicted RNA polymerase II-specific DNA binding activity and its role in transcriptional regulation. | ||||||